Smart bomb for blood cancer: targeted therapy combo shows promise in early trial
NCT ID NCT06034470
First seen Feb 24, 2026 · Last updated Apr 30, 2026 · Updated 9 times
Summary
This early-phase study tests a new targeted drug (PVEK) combined with standard chemotherapy for adults with aggressive, hard-to-treat blood cancers like acute myeloid leukemia (AML). The drug homes in on a marker found on cancer cells to deliver chemotherapy directly. The goal is to find the safest dose and see if the combo works better than standard treatment alone. About 30 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.